DAEJEON, South Korea and NORTH BETHESDA, Md., Oct. 31, 2025 (GLOBE NEWSWIRE) -- IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for ...

Antibody-Drug Conjugates (ADCs) are a fundamental technology in modern tumor-targeted therapy with their ‘tripartite integrated design’ of ‘precision carrier - stable linker - potent payload’: The ...

In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work than the perfunctory punctuation suggests. That hyphen stands for the ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Lonza is responsible for manufacturing proprietary tech components and Sidewinder for ADC, R&D, manufacturing, and commercialization.

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC) linker platform. The two companies have been working together ...

Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class ...

Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field. Leveraging IntoCell's proprietary drug-linker technologies alongside ...

Data supporting the rationale for Baylink's innovative ADC linker technology enabling delivery of degraders, dual payload antibody drug conjugates, and high drug to antibody ratio chemotherapy will be ...